Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update in pulmonary vascular diseases 2013.

Literature DB >> 25271744

Update in pulmonary vascular diseases 2013.

Paul M Hassoun¹, Paul T Schumacker.

Abstract

Entities: Disease

Mesh：

Year: 2014 PMID： 25271744 PMCID： PMC5446203 DOI： 10.1164/rccm.201405-0871UP

Source DB: PubMed Journal: Am J Respir Crit Care Med ISSN： 1073-449X Impact factor: 21.405

× No keyword cloud information.

33 in total

1. Death in pulmonary arterial hypertension.

Authors: Ronald J Oudiz
Journal: Am J Respir Crit Care Med Date: 2013-08-01 Impact factor: 21.405

2. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

Authors: Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko
Journal: Am J Respir Crit Care Med Date: 2013-07-15 Impact factor: 21.405

3. Mitochondria in hypoxic pulmonary vasoconstriction: potential importance of compartmentalized reactive oxygen species signaling.

Authors: Mark N Gillespie; Abu-Bakr Al-Mehdi; Ivan F McMurtry
Journal: Am J Respir Crit Care Med Date: 2013-02-15 Impact factor: 21.405

4. Are tyrosine kinase inhibitors the better serotonin inhibitors?

Authors: Djuro Kosanovic; Ralph Schermuly
Journal: Am J Respir Crit Care Med Date: 2013-01-01 Impact factor: 21.405

5. A novel channelopathy in pulmonary arterial hypertension.

Authors: Lijiang Ma; Danilo Roman-Campos; Eric D Austin; Mélanie Eyries; Kevin S Sampson; Florent Soubrier; Marine Germain; David-Alexandre Trégouët; Alain Borczuk; Erika Berman Rosenzweig; Barbara Girerd; David Montani; Marc Humbert; James E Loyd; Robert S Kass; Wendy K Chung
Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245

6. Riociguat for the treatment of pulmonary arterial hypertension.

Authors: Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245

7. Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension.

Authors: Monika Malczyk; Christine Veith; Beate Fuchs; Katharina Hofmann; Ursula Storch; Ralph T Schermuly; Martin Witzenrath; Katrin Ahlbrecht; Claudia Fecher-Trost; Veit Flockerzi; Hossein A Ghofrani; Friedrich Grimminger; Werner Seeger; Thomas Gudermann; Alexander Dietrich; Norbert Weissmann
Journal: Am J Respir Crit Care Med Date: 2013-12-15 Impact factor: 21.405

2. Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension.

Authors: Jeffrey D Marshall; Maor Sauler; Adriano Tonelli; Youlan Rao; Richard Bucala; Patty J Lee; Wassim H Fares
Journal: Pulm Circ Date: 2017-07-31 Impact factor: 3.017

2 in total

Update in pulmonary vascular diseases 2013.

1. Death in pulmonary arterial hypertension.

2. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

3. Mitochondria in hypoxic pulmonary vasoconstriction: potential importance of compartmentalized reactive oxygen species signaling.

4. Are tyrosine kinase inhibitors the better serotonin inhibitors?

5. A novel channelopathy in pulmonary arterial hypertension.

6. Riociguat for the treatment of pulmonary arterial hypertension.

7. Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension.

8. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells.

9. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis.

10. Causes and circumstances of death in pulmonary arterial hypertension.

1. Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.

2. Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension.